U.S. stock market update: Liminatus Pharma up 25.18%

U.S. Stock Market Midday Update Liminatus Pharma, up 25.18%, with increased trading volume. Based on recent key news: On June 12, executives from China National Pharmaceutical Group revealed at the Goldman Sachs Global Healthcare Conference that a landmark external licensing deal is expected to be finalized soon, driving the stock price up. On May 19, a block trade occurred for Lino Pharmaceutical, with shareholders increasing their holdings, leading to a 14.25% rise in stock price. On May 20, a block trade occurred for TuoXin Pharmaceutical, resulting in a 0.89% increase in stock price. Stocks with High Trading Volume in the Industry AbbVie, up 0.53%, with increased trading volume. Based on recent important news: On August 22, AbbVie announced that its alopecia treatment drug Rinvoq achieved primary goals in two key late-stage trials, driving the stock price up 0.88%. On August 21, a large purchase of AbbVie stock was made on behalf of Ritchie Torres, boosting market confidence. On August 19, AbbVie completed its acquisition of Capstan Therapeutics, expanding its product line. Ethzilla, down 37.42%, with a trading volume of $61.07 million. Based on recent key news: On August 22, Ethzilla shareholders applied to sell 74.8 million convertible shares, causing the stock price to drop nearly 38%. In August, Ethzilla completed a private placement, raising $425 million to purchase Ethereum and continue its iGaming business. In August, Ethzilla announced it holds 82,186 Ethereum, with an average acquisition price of $3,806.71, currently valued at approximately $349 million. Biohaven Pharmaceuticals, up 5.38%, with increased trading volume. Based on recent important news: On August 22, Biohaven announced that its new drug troriluzole is expected to receive FDA approval by the end of the year, becoming the first drug to treat spinocerebellar ataxia, resulting in a 5.6% increase in stock price. On August 22, Biohaven submitted new drug application documents to the U.S. Securities and Exchange Commission, which was positively received by the market. On August 22, Biohaven's stock price rose 11.65% in pre-market trading, reflecting investor optimism about its new drug prospects. Stocks with High Market Capitalization in the Industry Amgen, up 0.70%, with a market capitalization of $159.1 billion, and increased trading volume. Based on recent key news: On August 21, Amgen released its latest financial report, showing that its quarterly revenue and profit exceeded market expectations, driving the stock price up 0.70% On August 20th, MarketBeat reported that although Amgen was rated as a hold, top analysts recommended five other stocks, leading some investors to reassess their portfolios. On August 22nd, the futures market was dominated by bulls, with the funding rate turning positive and the long-short ratio rising to 1.169, indicating an increase in bullish sentiment in the market, further supporting Amgen's stock price